The Goldman Sachs Group Reiterates Buy Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating restated by research analysts at The Goldman Sachs Group in a report released on Wednesday,MarketScreener reports.

Other research analysts have also recently issued reports about the stock. Truist Financial set a $155.00 price target on shares of BioNTech in a research report on Tuesday. UBS Group upgraded shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Jefferies Financial Group decreased their price objective on BioNTech from $151.00 to $138.00 and set a “buy” rating for the company in a report on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.73.

BioNTech Price Performance

BioNTech stock opened at $90.10 on Wednesday. The business has a fifty day moving average price of $106.54 and a 200-day moving average price of $102.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.02. The firm has a market capitalization of $20.29 billion, a P/E ratio of -17.19 and a beta of 1.51. BioNTech has a one year low of $79.52 and a one year high of $124.00.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently bought and sold shares of BNTX. Hsbc Holdings PLC purchased a new position in shares of BioNTech in the fourth quarter valued at about $4,969,000. Caitong International Asset Management Co. Ltd grew its position in shares of BioNTech by 1,012.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after purchasing an additional 506 shares in the last quarter. Sankala Group LLC bought a new stake in BioNTech during the 4th quarter valued at approximately $248,000. Virtu Financial LLC lifted its holdings in BioNTech by 163.9% in the 4th quarter. Virtu Financial LLC now owns 11,244 shares of the company’s stock worth $1,070,000 after purchasing an additional 6,984 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in BioNTech by 9.0% in the 4th quarter. Invesco Ltd. now owns 80,841 shares of the company’s stock worth $7,696,000 after purchasing an additional 6,685 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord reiterated a “buy” rating and set a high $171 price target, signaling strong upside relative to the current level and supporting bullish investor thesis on long‑term mRNA opportunity. Canaccord reaffirms buy, $171 PT
• Positive Sentiment: Goldman Sachs reaffirmed its “buy” rating, providing another institutional vote of confidence that may stabilize sentiment among growth‑oriented holders. Goldman Sachs reaffirms buy
• Positive Sentiment: BioNTech and its co‑founders announced plans to pursue next‑generation mRNA innovations — a strategic signal that the company is investing in future product pipelines beyond COVID vaccines. Co‑founders pursue next‑gen mRNA
• Neutral Sentiment: Independent write‑ups are debating whether recent weakness makes BNTX a value play; the analysis highlights multi‑period share declines but leaves valuation conclusions to readers. Yahoo analysis on BNTX valuation
• Neutral Sentiment: Data feeds flagged a “large increase” in short interest, but the published figures are inconsistent (zeros/NaN and 0.0 days to cover), suggesting a likely reporting glitch rather than actionable short‑squeeze pressure.
• Neutral Sentiment: BMO trimmed its price target (to $128) but kept an “outperform” stance — a modest downgrade in optimism rather than a rout. BMO lowers PT to $128
• Negative Sentiment: Several outlets reported a steep share drop after an earnings miss and leadership changes (founder departures); that combination typically triggers near‑term selling and raises execution risk. Earnings miss & founder exodus — Blockonomi Earnings miss & leadership change — Tokenist
• Negative Sentiment: Multiple sell‑side revisions trimmed expectations: Citigroup lowered its PT to $130 (still a “buy”), TD Cowen cut to $94 and moved to “hold”, and Jefferies published more cautious forecasts — collectively cooling near‑term analyst enthusiasm. Citigroup cuts PT to $130 TD Cowen cuts to $94 Jefferies lowers expectations

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.